NRG-GY029, "A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) with PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients with Recurrent Platinum Resistant Ovarian, Fallopian, Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy" (NCT TBD)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 22-1568
More information available at ClinicalTrials.gov: NCT05295589
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers